[Chloroquine Neuromyopathies: 4 Cases During Antimalarial Prevention]
Overview
Affiliations
Four cases of chloroquine neuropathy presented two points of particular interest: 1) these were all young women with strictly prophylactic doses of chloroquine (100 mg/24 h); two patients showed pronounced loss of weight; 2) signs of myogenic lesions were apparent in only one patient whereas clinical and electric signs of neurogenic involvement were observed in all 4 cases. Biopsy in 3 patients (muscle in one and muscle and nerve in two) failed to show characteristic vacuoles; in one case mild segmental demyelinization was present. A favorable course was obtained in all cases after discontinuation of chloroquine, with dramatic recovery from the motor deficit. Pharmacokinetic studies in 1 patient showed abnormally high chloroquine levels at initial assay with slow elimination after its discontinuation.
Hydroxychloroquine: A double‑edged sword (Review).
Huo R, Wei C, Yang Y, Lin J, Huang X Mol Med Rep. 2025; 31(4).
PMID: 39981928 PMC: 11868775. DOI: 10.3892/mmr.2025.13467.
Muller R Rheumatol Int. 2021; 41(7):1189-1202.
PMID: 33893862 PMC: 8064887. DOI: 10.1007/s00296-021-04868-6.
Morphological study of peripheral nerve changes induced by chloroquine treatment.
Tegner R, Tome F, Godeau P, LHERMITTE F, Fardeau M Acta Neuropathol. 1988; 75(3):253-60.
PMID: 2831692 DOI: 10.1007/BF00690533.
Prevention and management of drug-induced peripheral neuropathy.
Olesen L, Jensen T Drug Saf. 1991; 6(4):302-14.
PMID: 1653573 DOI: 10.2165/00002018-199106040-00007.